Differentiating the Effect of Medication and Illness on Brain Volume Reductions in First-Episode Psychosis: A Longitudinal, Randomized, Triple-blind, Placebo-controlled MRI study
Vanessa L. Cropley,
Hok Pan Yuen,
Stephen J Wood,
Posted 23 Mar 2020
medRxiv DOI: 10.1101/2020.03.18.20038471
Posted 23 Mar 2020
BackgroundPsychotic disorders are associated with reductions in brain volume, but the timing and causes of these reductions remain unclear. In particular, the effects of antipsychotic medication and illness have been difficult to disentangle due to a lack of prospective, longitudinal, randomized placebo-controlled designs. MethodsWe conducted a triple-blind randomised placebo-controlled trial where 62 antipsychotic naive patients with first episode psychosis (FEP) received either an atypical antipsychotic or a placebo pill over a treatment period of 6 months. Both FEP groups received intensive psychosocial therapy. A healthy control group (n=27) was also recruited. Structural MRI scans were obtained at baseline, 3-months and 12-months. Our primary aim was to differentiate illness-related brain volume changes from medication-related changes within the first 3 months of treatment. We secondarily investigated long-term effects at the 12-month timepoint. OutcomeFrom baseline to 3 months, we observed a significant group x time interaction in the pallidum, such that patients receiving atypical antipsychotics showed increased volume, patients on placebo showed decreased volume, and healthy controls showed no change. In patients, a greater increase in pallidal grey matter volume over 3 months was associated with a greater reduction in symptom severity, consistent with a neuroprotective effect of atypical antipsychotics. We additionally found preliminary evidence for illness-related volume reductions in prefrontal cortices at 12 months and putative antipsychotic-related neurotoxicity in cerebellum at both 3-months and 12-months. InterpretationOur findings indicate that psychotic illness and antipsychotic exposure exert distinct and spatially distributed effects on brain volume. Our results align with prior work in suggesting that the therapeutic efficacy of antipsychotics may be primarily mediated through their effects on the basal ganglia. Trial registrationACTRN12607000608460.
- Downloaded 497 times
- Download rankings, all-time:
- Site-wide: 84,415
- In psychiatry and clinical psychology: 341
- Year to date:
- Site-wide: 158,552
- Since beginning of last month:
- Site-wide: 143,209
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!